Live Analyst Rating Changes 22588 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/James Gordon CFA
BARC

James Gordon CFA

Barclays
Wall Street Analyst
★★★☆☆
#1565
on 13Foresight · ranked by our own returns
51%
Success Rate
-1.1%
Average Return
18 of 35 calls profitable · -3.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 51% of James Gordon CFA's ratings turned a profit when each position was held for 1 year — averaging -1.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

67 Buy 33 Hold 27 Sell
James's Stock Coverage 15 ratings · 2026-08-11
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GB:0MGB
Genmab A/S
 Aug 10, 2026 BUY Buy
-0.1% avg upside
23 analysts
$2500.00
25.03% Upside
 · ·
GMAB
Genmab
 Aug 07, 2026 BUY Buy
+16.4% avg upside
27 analysts
 — +0.0% ·
CH:SDZ
Sandoz Group Ltd
 Aug 06, 2026 BUY Buy
-7.0% avg upside
11 analysts
$81.00
12.15% Upside
 +0.0% ·
GB:0QIU
Novo Nordisk
 Aug 06, 2026 HOLD Hold
+35.1% avg upside
29 analysts
$310.00
1.64% Upside
 · ·
GB:GSK
GlaxoSmithKline
 Aug 04, 2026 SELL Hold
-0.1% avg upside
25 analysts
$1900.00
1.36% Downside
 -1.1% ·
GB:0QW0
arGEN X
 Jul 29, 2026 BUY Strong Buy
-20.4% avg upside
24 analysts
$980.00
26.77% Upside
 · ·
GB:AZN
AstraZeneca
 Jul 28, 2026 BUY Strong Buy
+21.5% avg upside
26 analysts
$16500.00
37.59% Upside
 -9.8% ·
CH:GALD
Galderma Group AG
 Jul 24, 2026 BUY Strong Buy
+4.7% avg upside
10 analysts
$210.00
19.41% Upside
 +2.7% ·
ARGX
Argenx Se
 Jul 24, 2026 BUY Strong Buy
-9.8% avg upside
47 analysts
$950.00
9.65% Upside
 -5.8% ·
CH:NOVN
Novartis AG
 Jul 22, 2026 HOLD Buy
-12.4% avg upside
32 analysts
$125.00
1.51% Downside
 -1.9% ·
SE:SOBI
Swedish Orphan Biovitrum AB
 Jul 03, 2026 BUY Strong Buy
-0.3% avg upside
7 analysts
$530.00
17.75% Upside
 -7.1% ·
GB:HIK
Hikma Pharmaceuticals
 Jun 23, 2026 SELL Buy
+40.4% avg upside
8 analysts
$1350.00
18.11% Downside
 -11.3% ·
CH:ROP
Roche Holding AG
 May 26, 2026 BUY Buy
-10.0% avg upside
23 analysts
$410.00
9.95% Upside
 +10.2% ·
FR:SAN
Sanofi
 Apr 23, 2026 HOLD Strong Buy
+29.8% avg upside
30 analysts
$85.00
12.52% Upside
 -2.0% ·
NL:LKFT
Galapagos
 Jan 23, 2025 SELL Sell
+122.5% avg upside
16 analysts
$22.00
6.09% Downside
 -29.2% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
James Gordon CFA — Frequently Asked Questions
How accurate are James Gordon CFA's stock ratings?
Based on the calls 13Foresight could measure, about 51% of James's ratings were profitable over a one-year hold, with an average return of -1.1% per rating, or -3.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is James ranked on 13Foresight?
James Gordon CFA is currently ranked #1565 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on GB:0MGB, GMAB, CH:SDZ, GB:0QIU, GB:GSK, GB:0QW0, GB:AZN, CH:GALD, ARGX, CH:NOVN, SE:SOBI, GB:HIK and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.